Free Trial

GeneDx Q2 2024 Earnings Report

GeneDx logo
$77.40 +2.10 (+2.79%)
(As of 12/20/2024 05:31 PM ET)

GeneDx EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.26
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

GeneDx Revenue Results

Actual Revenue
$70.51 million
Expected Revenue
$58.90 million
Beat/Miss
Beat by +$11.61 million
YoY Revenue Growth
N/A

GeneDx Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

>> Register for the Workshop Now

GeneDx Earnings Headlines

The top five midcap stocks of 2024
Amazon coin set to soar 25X – starting December 16th?
This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team of crypto experts has identified it as the most promising crypto of 2024. You can see all of the details surrounding the #1 Crypto of 2024
GeneDx Rides Revenue Surge, But Valuation Risks Loom
GeneDx expands access to exome testing for pediatric epilepsy patients
See More GeneDx Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GeneDx? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GeneDx and other key companies, straight to your email.

About GeneDx

GeneDx (NASDAQ:WGS), through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.

View GeneDx Profile

More Earnings Resources from MarketBeat

Upcoming Earnings